Solid tumors
Conditions
Interventions
GPDC treatment group:basal treatment
Sponsors
The second people's hospital of Neijiang
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years old; 2. Histologically confirmed solid tumors; 3. Fresh tumor tissue =6g; 4. ECOG PS 0-2; 5. The main organ function properly and meet the following requirements: blood tests must meet(within 14 days without blood transfusion) HB=90g/L; ANC =1.5×10^9/L; PLT =80 ×10^9/L; biochemical tests subject to the following criteria: BIL <1.5 times the upper limit of normal (ULN); ALT and AST <2.5 ×ULN; if liver metastases, the ALT and AST <5 ×ULN; serum Cr=1 ×ULN, creatinine clearance =50ml / min (Cockcroft-Gault formula); 6. The expected survival = 6 months; 7. No active infection within two weeks; 8. Treating physician plans to use GPDC; 9. Patient volunteered to join the study and signed informed consent (ICF).
Exclusion criteria
Exclusion criteria: 1. patients with severe liver or kidney dysfunction or heart failure; 2. patients with autoimmune disease that need for systemic use of immunosuppressive agents or hormone therapy; 3. patients experienced adverse reactions, or serious adverse events; 4. abnormal coagulation function (INR>1.5 * ULN, ULN * APTT>1.5), with bleeding tendency or active bleeding patients; 5. there are active brain metastases; 6. tumor tissue < 6g, unable to prepare gp96 antigen peptide complex; 7. Contamination occurred during gp96 antigen peptide complex preparation(including bacteria, viruses, fungi, etc.); 8. Contamination occurred during DC extraction or in vitro sensitization DC(including bacteria, viruses, fungi, etc.); 9. storage transport of gp96 antigen peptide complex or DC is not in accordance with the requirements of the experiment; 10. patients voluntarily withdraw from this study; 11. pregnant or lactating women; 12. Other treating physician believes the patient is not fit for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fundus examination;Liver function damage;Renal function damage;Body temperature rise;Autologous antibody;Immunology index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;Objective remission rate;Progression free survival;overallsurvival;Time To Progress;Quality of life; | — |
Countries
China
Contacts
Public ContactOu Jiang
The second people's hospital of Neijiang
Outcome results
None listed